FDA Updates Phase 1 IND FAQ, Clarifying Clinical Hold Triggers and Nonclinical Data Requirements

Regulatory affairs teams preparing first-in-human submissions now have a consolidated FDA reference point: the agency has published an updated Phase 1 IND FAQ that addresses clinical hold triggers, nonclinical data thresholds, and IND exemption criteria, areas where submission gaps most commonly stall programs ahead of 21 CFR 312 review.

The FAQ confirms that nonclinical packages must adequately characterize a drug's safety profile and justify the proposed starting dose and study design. FDA directs sponsors to ICH M3(R2) and ICH S6(R1) for general scientific considerations around study type and timing, while emphasizing that the specific data burden is risk-stratified, shaped by intended clinical population, product modality, and mechanism of action. That risk-based framing gives RA leads latitude, but also places the justification burden squarely on the sponsor's nonclinical narrative.

On clinical holds, the FAQ itemizes common Phase 1 triggers without prescribing an exhaustive list, signaling that CDER retains discretion. For QA and regulatory teams, the practical read is that incomplete pharmacology and toxicology sections remain the most frequent hold catalyst, a point consistent with longstanding 21 CFR 312.23(a)(8) requirements. The FAQ also clarifies the 30-day IND review window: drug administration may not begin until that period lapses or FDA provides earlier clearance.

The document addresses several procedural questions relevant to operations: IND amendment protocols, safety reporting expectations, IRB review obligations for marketed-product investigations, and whether real-world data studies require an IND. Sponsors are directed to CDER's Phase 1 Clinical Trials Support Team, reachable at [email protected] or 240-276-9358, for case-specific queries that fall outside FAQ scope.

Notably, FDA reiterates its position supporting animal-use reduction strategies in nonclinical development, encouraging sponsors to leverage publicly available data to optimize safety evaluation. This aligns with CDER's broader 3Rs framework and may affect how sponsors structure toxicology packages for novel modalities.

Regulatory teams finalizing pre-IND meeting requests or assembling Phase 1 packages should cross-reference the updated FAQ against current pharmacology and toxicology submission standards before the next CDER review cycle.

Source: FDA CDER via FDA.gov What's New: Drugs RSS Feed, October 9, 2026.